Folklore vs Lyfegen HealthTech AG: Which Is Better in 2026?

Folklore by Helena Bioinformatics is a free public web tool for automated ACMG/AMP classification of individual human germline variants on GRCh38. Enter a supported HGVS expression, SPDI, rsID or genomic coordinate for a nuclear SNV or simple insertion or deletion smaller than 50 bp. When the variant resolves uniquely and interpretation succeeds, Folklore shows the normalized variant, the automated classification and reported criteria, and available evidence such as ClinVar assertions and population allele frequencies, with source versions. ClinVar assertions are displayed separately from the automated classification. No account is required for public single-variant queries. Clinical use of a result requires review by a qualified genetics professional.

The public service is available at https://folklore.helena.bio/. Its browser interface lets a visitor start with one variant identifier and inspect the returned interpretation and supporting annotations. This makes the service relevant to researchers, genetics professionals and learners looking for an accessible way to explore ACMG/AMP variant classification and the evidence reported for a supported variant. The public workflow concerns a single variant on the GRCh38 reference assembly.

The distinction between automated classification and existing database assertions matters when reading a result. Folklore presents ClinVar assertions separately, so visitors can examine those records alongside the automated interpretation rather than treating them as the same conclusion. Available source versions and supporting evidence help readers understand the information behind a result. Evidence availability and successful interpretation depend on the submitted variant; a uniquely resolved input and a successful query are necessary before an interpretation can be shown.

Visitors can read the public guide at https://folklore.helena.bio/acmg-variant-classification and a worked example at https://folklore.helena.bio/examples/acmg-variant-classification before submitting their own supported query. These pages explain the public single-variant workflow and provide a concrete example of the information to review. The public browser service is free to access without registration. Its automated output should be reviewed in the relevant clinical and scientific context by a qualified genetics professional before clinical use.

Lyfegen is an independent provider of cloud-based rebate management, drug pricing, and market access software designed for the healthcare industry. Founded in 2018 and headquartered in Basel, Switzerland, Lyfegen supports organizations across Europe, North America, and the Middle East.

Its solutions are used by health insurers, governments, hospital payers, and pharmaceutical companies to simplify complex drug pricing agreements, reduce administrative work, improve rebate compliance, and generate greater value from healthcare contracts. Payers and pharmaceutical companies are among Lyfegen’s key target customers.

Lyfegen’s platform combines rebate management and analytics, a drug contracting simulator, and a comprehensive agreements library. Its rebate management capabilities help healthcare organizations validate, analyze, and manage rebates more efficiently while reducing reliance on manual processes and improving financial oversight.

The drug contracting simulator allows users to model and compare different pricing, reimbursement, and contracting scenarios before agreements are implemented. Teams can test assumptions, assess potential financial outcomes, and evaluate different contract structures to support more informed pricing and negotiation decisions.

Lyfegen also maintains a large digital repository of innovative drug pricing models and publicly available agreements. This knowledge base helps users review existing approaches, conduct due diligence, benchmark potential agreements, and identify relevant contracting models across different healthcare markets.

The platform also supports value-based contracting and other innovative access models by helping organizations manage the design, implementation, monitoring, and analysis of complex agreements. By bringing these processes into one cloud-based environment, Lyfegen helps reduce administrative burden, improve transparency, and strengthen collaboration between healthcare stakeholders.

For pharmaceutical companies, Lyfegen supports pricing, market access, contracting, and rebate management activities. For payers, governments, insurers, and hospital organizations, the platform supports contract evaluation, rebate validation, financial analysis, and agreement management.

By combining simulation, analytics, rebate management, and market intelligence, Lyfegen helps healthcare organizations make more informed pricing and reimbursement decisions while making pharmaceutical contracting more efficient, transparent, and manageable.

What problem it solves

Lyfegen solves the complexity and administrative burden of managing drug pricing agreements, rebates, and value-based contracts in healthcare. Many payers and pharmaceutical companies still rely on fragmented systems, spreadsheets, and manual processes to design, monitor, validate, and analyze these agreements.

Lyfegen centralizes these activities in one cloud-based platform, helping organizations manage rebates more efficiently, simulate different pricing and contracting scenarios, improve compliance, and gain clearer visibility into the financial impact of their agreements. It also helps healthcare stakeholders reduce manual work, improve collaboration, and make more informed pricing, reimbursement, and market access decisions.